These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31. Souhami L; Bae K; Pilepich M; Sandler H Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1301-6. PubMed ID: 20356687 [TBL] [Abstract][Full Text] [Related]
26. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258 [TBL] [Abstract][Full Text] [Related]
27. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer. Nguyen MM; Wang Z Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432 [TBL] [Abstract][Full Text] [Related]
28. Secondary hormonal therapy. Smith DC Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134 [TBL] [Abstract][Full Text] [Related]
29. The benefits of early androgen blockade. Maroni PD; Crawford ED Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789 [TBL] [Abstract][Full Text] [Related]
30. The role of chemotherapy in prostate cancer. Minireview. Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822 [TBL] [Abstract][Full Text] [Related]
31. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Labrie F; Bélanger A; Luu-The V; Labrie C; Simard J; Cusan L; Gomez J; Candas B Endocr Rev; 2005 May; 26(3):361-79. PubMed ID: 15867098 [TBL] [Abstract][Full Text] [Related]
32. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626 [TBL] [Abstract][Full Text] [Related]
33. Current treatment of advanced prostate cancer. Ismail M; Gomella LG Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220 [TBL] [Abstract][Full Text] [Related]
34. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI; J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365 [TBL] [Abstract][Full Text] [Related]
35. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist. Boudreaux KJ; Chang SS BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172 [No Abstract] [Full Text] [Related]
36. Primary androgen deprivation therapy in men with prostate cancer. Laufman L JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809 [No Abstract] [Full Text] [Related]
37. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Okihara K; Ukimura O; Kanemitsu N; Mizutani Y; Kawauchi A; Miki T; Int J Urol; 2007 Feb; 14(2):128-32. PubMed ID: 17302569 [TBL] [Abstract][Full Text] [Related]
38. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112 [TBL] [Abstract][Full Text] [Related]